Sensei Biotherapeutics Inc (FRA:407)
€ 0.367 0 (0%) Market Cap: 10.90 Mil Enterprise Value: -29.88 Mil PE Ratio: 0 PB Ratio: 0.26 GF Score: 29/100

Sensei Biotherapeutics Inc at Piper Sandler Healthcare Conference Transcript

Dec 01, 2022 / 07:00PM GMT
Release Date Price: €1.37 (+1.70%)
Joe Catanzaro
Piper Sandler - Analyst

Okay. Perfect. Well, thanks so much, everybody, joining us here at the Piper Sandler's Annual Healthcare Conference. I'm Joe Catanzaro, one of the analysts here at Piper on the biotech side of things. And it's my real pleasure to welcome Sensei Biotherapeutics. With us, we have their President and CEO, John Celebi.

John, thanks so much for making the time. A number of things I want to sort of run through here in the next 25 minutes or so that we have. But maybe I can give you a quick opportunity to just sort of introduce then say what you guys are up to and what we have to look forward to.

John Celebi
Sensei Biotherapeutics, Inc. - President & CEO

Thank you, Joe. Good to be with you and thank you for the invitation to the fireside chat. Sensei is a immuno-oncology company. We're focused on generating conditionally active antibodies that only are active within the tumor microenvironment. We're particularly focused on an immune checkpoint called VISTA; we're very excited about that target. And we are only

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot